Valor202020212022202320242025TTMGastos comerciales, generales y administrativos11.29 B15.23 B18.42 B19.22 B19.98 B19.93 B—Investigación y desarrollo5.99 B9.74 B9.76 B10.94 B13.58 B14.23 B—Beneficio operativo5.16 B1.06 B3.76 B8.19 B10 B13.74 B—Total de ingresos no operativos———————Gastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses———————Ingresos/gastos extraordinarios———————Beneficio antes de impuestos3.92 B265 M2.5 B6.9 B8.69 B12.4 B—Participación en los beneficios———————Impuestos772 M380 M792 M938 M1.65 B2.17 B—Participación minoritaria52 M3 M5 M6 M6 M8 M—Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Operaciones suspendidas———————Beneficio neto3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Ajuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas———————Beneficio básico por acción———————Beneficio por acción diluido———————Número medio de acciones ordinarias———————Acciones diluidas———————EBITDA———————EBIT———————Costo de los ingresos5.3 B12.44 B12.39 B8.27 B10.21 B10.63 B—Otros costes de producción———————Amortización y depreciación (flujo de caja)———————
AstraZeneca PLC - American Depositary Shares
AstraZeneca plc is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje.